AMG 557

Drug Profile

AMG 557

Alternative Names: AMG 557/MEDI5872; AMG-557; Anti-B7RP1 MAb; MEDI-5872

Latest Information Update: 23 Jul 2017

Price : $50

At a glance

  • Originator Amgen
  • Developer Amgen; MedImmune
  • Class Monoclonal antibodies
  • Mechanism of Action B7-related protein 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Sjogren's syndrome
  • Phase I Systemic lupus erythematosus
  • Discontinued Cutaneous lupus erythematosus; Psoriasis

Most Recent Events

  • 14 Jun 2017 Adverse events, pharmacokinetics and efficacy data from a phase I trial in System lupus erythematosus presented at the 18th Annual Congress of the European League Against Rheumatism (EULAR-2017)
  • 20 Apr 2016 Amgen completes its phase I trial for Systemic lupus erythematosus in USA, United Kingdom, Denmark, Germany, France, Malaysia, Taiwan and Australia (NCT01683695)
  • 24 Sep 2015 Phase-II clinical trials in Sjogren's syndrome in France (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top